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Activity of the angiotensin converting enzyme 
(ACE) is usually measured in vitro by estimation of 
products cleaved by the enzyme from synthetic 
substrates. These substrates have affinities for ACE 
different from the natural substrate angiotensin I, 
and insensitive detection systems necessitate milli-
molar substrate concentrations while physiological 
angiotensin I concentrations are in the picomolar 
range. 
A new assay for ACE activity measurement was 
developed which reliably quantitates femtomoles 
of generated angiotensin II in plasma from angio­
tensin I added at a 17 pmol/mL concentration. The 
production of high affinity monoclonal antibodies 
against angiotensin II (Kd = 7 X 1 0 " 1 1 mol/L) al­
lowed a quantitative trapping (and thus protection 
from degrading enzymes) of angiotensin II gener­
ated during the incubation step and subsequent ra­
dioimmunoassay by simple dilution with labelled 
angiotensin II. 
Using 40 //L plasma, the detection limit was 20 
fmol/mL/min. Normal human plasma has an ACE 
activity of 335 ± 83 fmol/mL/min (mean ± SD). 
Precision was characterized by coefficients of varia­
tion of ^ 11% both within-assay and between-
assays. Accuracy of the new method was estab­
lished by comparing ACE activity with the ratio of 
plasma angiotensin II/angiotensin I in plasma ob­
tained from normal volunteers 0.5 to 24 h after oral 
administration of 20 mg enalapril. The percentage 
of ACE inhibition indicated by both methods was 
almost identical (r = 0.93, η = 60, Ρ < .001). Since 
the latter ratio appears to reflect in vivo ACE activ­
ity, these results indicate that accurate measure­
ment in vitro of ACE activity in vivo has been 
achieved. Am J Hypertens 1992;5:393-398 
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In vitro measurement of the enzyme activity of an­giotensin converting enzyme (ACE) in plasma and other biological samples is based on cleavage of synthetic substrates by the ACE. Products cleaved 
from these substrates under standardized reaction con­
ditions are quantitated in order to estimate ACE 
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activity. 1" 3 Over the last two decades, ACE inhibiting 
drugs became available and today are widely used for 
the treatment of hypertension and congestive heart fail­
ure. Plasma ACE activity is measured for drug mon­
itoring in patients treated with ACE inhibitors and the 
conventional methods used so far provided well-repro­
ducible results. However, in contrast to such consist­
ency in measurement (precision), absolute ACE activi­
ties were found to differ considerably (accuracy) when 
measured in a given plasma with different methods. 4 
Moreover, while the ratio of plasma concentrations of 
angiotensin (Ang) II to AngI can always be used as an 
indicator of ACE activity in vivo, 5 , 6 different methods of 
ACE activity measurement must be applied in vitro de­
pending on which particular ACE inhibitor is moni­
tored. This is necessary to obtain the appropriate paral­
lelism between results in vivo and in vitro.4 The 
inaccuracy of conventional methods may be caused by 
several factors: first, the substrates used are chemically 
different from the natural substrate angiotensin I; sec­
ond, the insensitive detection systems used to quantitate 
products cleaved by ACE from these substrates necessi­
tate very high substrate concentrations (millimolar); and 
third, the dilution of biological samples in vitro induces 
reaction conditions that are different from those in vivo. 
The present paper introduces a new and accurate 
method of measurement of ACE activity that overcomes 
the above-mentioned difficulties. Plasma ACE activity 
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FIGURE 1. Linearity of generation of angiotensin II in a plasma 
sample incubated at 37°C: generated angiotensin II is trapped by 
added high affinity monoclonal antibodies and protected against 
enzymatic degradation. Subsequent dilution makes it possible to 
quantitate angiotensin II radioimmunologically by using these 
antibodies. 
natural substrate angiotensin I at low nanomolar con­
centration. (For comparison, note that endogenous 
plasma angiotensin I levels may reach high picomolar 
concentrations after ACE inhibition). Femtomoles of 
generated angiotensin II are trapped by specific high 
affinity monoclonal antibodies and thus protected from 
degradation by angiotensinases during the incubation 
step. The same antibodies are subsequently used for 
quantitation by radioimmunoassay.7 
METHODS 
Study Protocol Ten normal human volunteers aged 20 
to 28 years (body weight 63 to 85 kg) participated in the 
study. On the study day, they came to the hospital at 7 
AM and were installed in the supine position. At 8 AM , the 
subjects ingested 20 mg enalapril, an inhibitor of angio­
tensin converting enzyme. Venous blood samples were 
collected before (time 0) and at 0.5, 1, 2, 4, 8, and 24 h 
after enalapril intake. Subjects remained in the supine 
position for 1 h prior to blood sampling and no food 
intake was permitted for the 3 h prior to sampling. 
Blood Sampling For the measurement of ACE activity, 
blood samples (5 mL) were collected from the antecubi-
tal vein into prechilled glass tubes containing heparin 
(56 USP) and 25 //L renin inhibitor CGP 29287 (Ciba-
Geigy, Basel, Switzerland) at a concentration of 
1 mmol/L water. Blood was centrifuged at 4°C and 
2000 g for 10 min and plasma aliquots of 0.5 mL were 
snap frozen in liquid nitrogen and stored at — 70 ° C until 
analyzed. 
For the measurement of Ang II 8 and immunoreactive 
Ang I, 9 another 10 mL blood were collected on an inhibi­
tor cocktail containing EDTA and renin inhibitor to pre­
vent degradation and generation of these peptides in 
vitra. Samples were centrifuged at 4°C and plasma ali­
quots of 2.2 mL snap frozen and stored as described 
above. 
Material Monoclonal antibodies against angiotensin II 
were produced by the somatic cell fusion technique 1 0 as 
previously described in detail. 1 1 However, we used SP 
2 / 0 myeloma cells and spleen lymphocytes of a C3H 
mouse hyperimmunized with Ang II coupled to bovine 
thyroglobulin.1 2 For the measurement of ACE activity, a 
high-affinity monoclonal angiotensin II antibody (Kd = 
7 Χ 1 0 ~ n mol/L) of the IgGl class was used which 
cross-reacted with the carboxyterminal fragments of 
Ang II at 75 to 105% and less than 1% with Ang I and 
aminoterminal fragments. No cross-reaction (below 
10~ 6 %) was found with angiotensinase inhibitors such 
as tripotassium ethylenediaminetetraacetate (EDTA, 
purchased from Fluka, Buchs, Switzerland) or bacitracin 
(Grossman Pharmaca, Basel, Switzerland). 
The albumin buffer consisted of a 0.1 mol/L Tris 
buffer (Sigma, St. Louis, MO) containing 5 g/L heat-in­
activated bovine serum albumin (Sigma), 20 mmol/L 
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TABLE 1. PLASMA CONVERTING ENZYME ACTIVITY AND ANGIOTENSIN CONCENTRATIONS IN 
HEALTHY HUMANS AFTER A SINGLE ORAL DOSE OF 20 mg ENALAPRIL (MEAN ± SEM, η = 10) 
Time After ACE Activity ACE Activity 
Enalapril Trapping Assay Conventional Assay Angiotensin I Angiotensin II Ang 11/Ang I 
Intake (h) (fmol/mL/min) (nmol/mL/min) (fmol/mL) (fmol/mL) Ratio 
0 335 ± 28 18.0 ± 1.6 8.2 ± 1.7 5.2 ± 0 . 6 0.780 ±0 .120 
0.5 295 ± 27 18.1 ± 1.7 7.3 ± 1.5 4.6 ± 0 . 5 0.748 ±0 .101 
1 107 ± 17 12.1 ± 1.2 13.5 ± 3 . 0 2.9 ± 0.5 0.315 ± 0.094 
2 28 ± 8 4.5 ± 0 . 8 45.7 ± 12.9 1.1 ± 0 . 3 0.029 ± 0.006 
4 15 ± 10 3.0 ± 0 . 4 66.8 ± 17.6 1.0 ± 0 . 2 0.015 ± 0.003 
8 5 ± 5 3.7 ± 0 . 4 76.6 ± 15.9 1.6 ± 0 . 4 0.016 ±0 .003 
24 87 ± 10 11.2 ± 1.0 32.1 ± 6 . 4 3.8 ± 0 . 5 0.147 ±0 .027 
bacitracin, and 200 mg/L sodium azide (Merck, Darm­
stadt, Germany). The pH was adjusted to 7.5 at room 
temperature. Angiotensin I and angiotensin II standard 
peptides were purchased from Peninsula Labs (St. 
Helens, Merseyside, England). 1 2 5 I-Ang II was obtained 
from New England Nuclear Inc. (Boston, MA). 
Measurement of Plasma ACE Activity All proce­
dures were done in an ice-water bath unless stated 
otherwise. Plasma was thawed and centrifuged at 4°C 
and 40 supernatant was pipetted into a small poly­
propylene tube. We added 10 μΙ., monoclonal antibody 
(mouse ascites diluted 1 :8400 in 3 mol/L Tris buffer at 
pH 7.3). We added 1 pmol angiotensin I in 10 //L albu­
min buffer. For blank determination, a duplicate 40 //L 
plasma sample was processed identically, but the albu­
min buffer contained in addition to angiotensin I also 
EDTA at a 0.2 mol/L concentration. After mixing and 
cold centrifugation in order to concentrate the mixture at 
the bottom of the tube (1 min at 2000 g) samples were 
incubated in a water bath at 37°C for 20 min. Incuba­
tion was stopped by returning the samples to the ice-
water bath. We added 40 //L albumin buffer without/ 
with 0.05 mol/L EDTA to blanks/samples in order to 
equalize conditions. Each tube (total 100 μΐ) finally re­
ceived 1 mL albumin buffer containing 1 fmol 1 2 5 I-Ang 
II (2000 counts/minute) and EDTA at 0.02 mol/L con­
centration. After a 24 h incubation at 4°C, antibody-
bound and free Ang II were separated by adding 0.3 mL 
water containing 2% dextran-coated charcoal, mixing 
for 10 min, centrifuging at 4°C (for 20 min at 6000 g), 
and decanting the supernatant. Supernatant and pellet 
were counted in a ten-well scintillation counter (Gam-
mamaster, Wallac, Turku, Finland) and generated Ang 
II was read from a simultaneously established standard 
curve. 
For the standard curve, increasing amounts of unla­
b e l e d Ang II ranging from 16 to 4000 fmol in 40 //L 
albumin buffer were added to 40 /iL pooled plasma that 
contained unmeasurably low endogenous Ang I and 
Ang II and renin inhibitor CGP 29287 at a 0.01 mmol/L 
concentration; we added antibody in a 3 mol/L Tris 
buffer (10 μΐ) and 1000 fmol Ang I in EDTA-albumin 
buffer (10 //L) in order to obtain conditions identical to 
the unknown samples. Plasma ACE activity was also 
measured by an established method using as substrate 
synthetic carbobenzoxy-Phe-His-Leu at 1.8 mmol/L 
concentration. 3 , 4 The ratio of the plasma concentrations 
Ang II/Ang I was used for estimation of ACE activity 
"in vivo". 6 
RESULTS 
Characteristics of Trapping-Assay for Plasma ACE 
Activity Sensitivity The present assay is optimized for 
a final dilution of the monoclonal antibody at 
1 :924,000. The smallest amount of unlabelled Ang II 
(16 fmol/tube) added to the standard curve results in 
antibody-binding of 5 0 % of the tracer angiotensin. This 
is more than two standard deviations less than tracer 
binding in the absence of unlabelled Ang II. Thus, the 
smallest possible amount of Ang II that can be read from 
the standard slope is 16 fmol. The theoretical detection 
limit for ACE activity in a 40 μΐ, plasma sample that was 
incubated for 20 min at 37°C is 20 fmol/mL/min 
(16 X 25/20) . The actual detection limit is zero, since 
EDTA-blanks may contain more than 16 fmol Ang II 
and these blanks are subtracted from Ang II generated 
during the incubation. 
Specificity ACE is a relative unspecific enzyme since it 
cleaves substrates other than Ang I, such as bradykinin 
or substance P. The present assay measures specifically 
Ang II (carboxyterminal-specific monoclonal antibody) 
and uses Ang I as substrate under conditions in vitro 
approaching those found in vivo. Endogenous Ang II is 
subtracted as well as Ang II generated in plasma despite 
renin inhibition and ACE inhibition by EDTA (blanks). 
Precision Within-assay precision was determined by 
repeated measurement within a single assay of plasma 
aliquots containing low, intermediate, or high ACE ac­
tivity (n = 10 each). The results were (mean ± SD) 
87.3 ± 9.4 fmol/mL/min, 144.9 ± 9.2 fmol/mL/min, 
205.5 ± 13.9 fmol/mL/min, and 389.0 ± 21.3 fmol/ 
mL/min, respectively. The corresponding coefficients 
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FIGURE 2. Assessment of converting enzyme (ACE) inhibition 
in vitro (ordinate) and in vivo (Ang II/Ang I): ACE activity in the 
plasma of 10 normal men up to 24 h after ingestion of 20 mg 
enalapril (n = 60). In vitro measurement by conventional proce­
dure using carbobenzoxy-Phe-His-Leu (Z-Phe-His-Leu) as sub­
strate (upper panel) underestimated ACE inhibition, whereas the 
new trapping method (lower panel) indicated similar ACE activ­
ity in vitro (A) as estimated in vivo (Q) by the ratio of plasma 
angiotensin II to angiotensin I. Plasma ACE activity before enala­
pril ingestion is A0 in vitro and Q0 in vivo. 
of variation (CV) for within-assay precision were 
10.8%, 6.4%, 6.8%, and 5.5%. Similarly, a plasma was 
analyzed on 24 different days and it was found to con­
tain an ACE activity of 228.6 ± 24.9 fmol/mL/min, ie, 
a CV for between-assay precision of 10.9%. 
Normal Values Plasma ACE activity in 22 normal 
human subjects was found to be 334.7 ± 82.9 fmol/ 
mL/min (mean ± SD) with a range between 178 and 
475. 
Linearity The linearity of the enzymatic reaction during 
incubation at 37°C was tested by incubating a normal 
plasma sample for 5, 8, 10 ,15 , 20, and 30 min at 37°C. 
Results are shown in Figure 1: there was a good linearity 
throughout the entire test period. 
Accuracy of Trapping Assay Table 1 shows the effect 
of a single oral dose of 20 mg enalapril in 10 volunteers 
on plasma ACE activity, plasma levels of Ang I and Ang 
II, and the ratio of plasma Ang II to Ang I. All parameters 
reached peak effects at 4 and 8 h after enalapril adminis­
tration. The ACE results obtained with the trapping 
method were well correlated with those obtained by the 
conventional method (r = 0.95, Ρ < .001). Convention­
ally measured ACE activity was related to but different 
from the plasma angiotensin II/angiotensin I ratio (Fig­
ure 2, upper panel). In contrast, the results of the trap­
ping method (y)—unlike conventionally obtained 
results — are virtually identical with ACE activity in 
vivo (x): y = 0.82x + 4.64 (Figure 2, lower panel). 
Measured ACE activities were expressed for every 
subject as a percent of baseline ACE activity and 
means ± SEM were calculated for each time point (Fig­
ure 3). In vivo ACE activity (ratio of plasma Ang II to 
Ang I) reached minima at 4 and 8 h after enalapril intake 
of 2.1 ± 0.3 and 2.0 ± 0.4%. On the following morning 
(24 h) in vivo ACE activity was still only 21.9 ± 5.0%. 
This was in excellent agreement with ACE activities 
measured in vitro with the trapping assay: 3.6 ± 2.4, 
1.3 ± 1.3, and 27.4 ± 3.4%. In contrast, the conven­
tional method for ACE activity measurement in vitro 
provided different results: at 4, 8, and 24 h after enala­
pril administration, plasma ACE activities were found to 
be at 16.5 ± 1.7, 20.8 ± 1.7 and 62.6 ± 1.6% of pre­
treatment values. 
DISCUSSION 
Accuracy of test results is a key issue for comparing the 
biochemical effects of different drugs of the same class 
of therapeutic agents. Most studies involving ACE inhib­
itors so far were endorsed by the established measure­
ment of plasma ACE activity using a high concentration 
of substrates with more or less affinity for the A C E . 1 - 3 
Recently, studies comparing the effects of different ACE 
inhibitors in normal volunteers provided evidence for 
the clear dependency of results on methods used for 
ACE measurement and the need for reliable measure­
ment of plasma angiotensin I and II has been empha­
sized. 4 , 6 Therefore an assay was developed which could 
accurately reflect ACE activity (and ACE inhibition) as 
found in the living organism and which would allow us 
to compare the efficacy of different ACE inhibitors. The 
present paper confirms our hypothesis that ACE activity 
AJH-JUNE 1992-VOL 5, NO. 6, PART 1 





(A/A 0 ) 
Mean + SEM Hours 
measured in vitro under more "physiological" condi­
tions is virtually identical with ACE activity in vivo. 
In our volunteers, the ratio of plasma Ang II and Ang I 
was used to estimate in vivo ACE activity. Activity de­
creased by 9 8 % at peak inhibition and returned to 22% 
ACE activity at 24 h. Very similar results were obtained 
for plasma ACE activity measured in vitro with the new 
method based on trapping by monoclonal antibodies of 
generated Ang II (decrease by 9 9 % at peak inhibition 
and return to 27% ACE activity at 24 h). In contrast, the 
conventional method of ACE activity estimation pro­
vided different results: peak ACE inhibition with only 
83% decrease from baseline and a substantial return 
towards baseline with 66% ACE activity at 24 h. Thus, 
the new method of ACE activity measurement provided 
more accurate results than the established method, if the 
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FIGURE 3. In vivo (dashed line) 
and in vitro (solid lines) plasma con­
verting enzyme (ACE) activity in 10 
normal men before and up to 24 h 
after ingestion of 20 mg enalapril In 
vivo ACE activity was estimated by 
the ratio of plasma angiotensin II to 
angiotensin I (Ang II/Ang I). In vitro 
measurement using the new trapping 
assay (Trapace, filled circles)gave vir­
tually identical results as those mea­
sured in vivo. Conventional measure­
ment of ACE activity in vitro using 
the substrate carbobenzoxy-Phe-
His-Leu (Z-Phe-His-Leu, open cir­
cles) underestimated ACE inhibition. 
η =10 
ratio of plasma Ang II/Ang I is accepted as a standard. 
Our results were obtained in subjects treated with ena­
lapril. Further experience must now be gained with 
other ACE inhibitors. Changes in endogenous angio­
tensin I concentration may have different impacts de­
pending on the ACE inhibitor used. The effect of the 
relationship between plasma and tissue ACE inhibition 
with different inhibitors remains to be established. If 
this method were to be adapted for measurement of 
ACE activity in tissues, serine protease inhibitors would 
have to be added during the incubation step to prevent 
angiotensin II generation by enzymes other than ACE. 
The new method of ACE activity measurement in 
vitro compares favorably with established procedures: 
femtomoles rather than nanomoles can be detected, 
which may be helpful in comparing the peak effects of 
different ACE inhibitors. The specificity of the proce-
dure is also greatly enhanced since it is based on a mono-
clonal antibody of unique specificity and affinity for 
Ang II and the natural substrate Ang I is used under 
conditions in vitro approaching those found in vivo. In 
comparison, conventional methods use diluted plasma 
and extremely high concentrations of substrates with 
affinities that are different from that of Ang I. Conven-
tional methods may therefore, in the presence of high-
affinity ACE inhibitors, lead to underestimation or 
overestimation of ACE inhibition. The Ang I concentra-
tion in almost undiluted plasma of the trapping assay is 
sufficient to warrant linearity of the Ang II production 
during the incubation step as demonstrated in Figure 2. 
The precision of the trapping method is not better than 
that of the conventional techniques, but coefficients of 
variation below 1 1 % for both within- and between-as-
say precision certainly demonstrate the validity of the 
new procedure. The high accuracy appears to be a major 
advantage of the trapping method. Finally, equipment 
needed for the new procedure is that of a routine radio-
immunoassay laboratory including a y-counter. Mono-
clonal antibodies and labelled and unlabelled angioten-
sins are or will be commercially available. 
In conclusion, we have introduced a reliable and accu-
rate new method for the measurement of plasma ACE 
activity that is based on the trapping of generated Ang II 
during the enzymatic reaction by high-affinity monoclo-
nal antibodies which are subsequently used to quanti-
tate the peptide by radioimmunoassay. 
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